<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01239368</url>
  </required_header>
  <id_info>
    <org_study_id>110016</org_study_id>
    <secondary_id>11-C-0016</secondary_id>
    <nct_id>NCT01239368</nct_id>
  </id_info>
  <brief_title>Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma</brief_title>
  <official_title>Rapamycin-Resistant T Cell Therapy of Multiple Myeloma: Relapse Prevention and Relapse Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hackensack Meridian Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      - Cancer development is associated with problems in immune system functions, which prevent
      the body from attacking and destroying the abnormal cells that lead to tumor growth. Research
      has suggested that certain white blood cells, known as Th1 (type 1 T helper cells) and Th2 T
      cells (type 2 T helper cells), are affected in individuals with some kinds of cancer -- when
      the proportion of Th2 cells is greater than Th1 cells, the immune systems ability to fight
      off the growth of malignant tumors is weakened. Researchers are interested in determining if
      an infusion of specially modified Th1 cells, in addition to stem cell transplant, is a safe
      and effective treatment for individuals with forms of multiple myeloma that might not respond
      well to standard treatments alone.

      Objectives:

      - To determine the safety and effectiveness of the infusion of modified Th1 white blood
      cells, in conjunction with standard treatment, as a treatment for individuals who have been
      diagnosed with high-risk forms of multiple myeloma.

      Eligibility:

        -  Individuals age 18 to 75 who have been newly diagnosed with high-risk multiple myeloma
           and who have received no or minimal treatment (Cohort A).

        -  Individuals age 18 to 75 who have relapsed multiple myeloma, as defined by measurable
           disease after at least 2 prior treatment regimens.

      Design:

        -  Participants will be screened with a medical history, physical examination, blood and
           urine tests, and imaging studies. Some participants may also have a bone marrow or other
           type biopsy to evaluate the state of their disease.

        -  White blood cells will be collected from the participants through an apheresis
           procedure, which will collect and separate the white blood cells and return the rest of
           the blood to the participant.

        -  The collected cells will be grown and expanded under special conditions in the
           laboratory and stored frozen until participants receive standard of care treatment for
           multiple myeloma, including a stem cell transplant.

        -  Participants will receive an infusion of the modified Th1 cells a few weeks after the
           transplant, and will remain in the hospital for a few days after receiving the cells to
           monitor the possible immediate effects of the treatment.

        -  Participants will have regular follow-up visits to study the long-term effects of the
           modified Th1 cell infusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

        -  Autologous Hematopoietic Cell Transplantation (AHCT), which represents the standard of
           care for newly diagnosed Multiple Myeloma (MM), is not curative therapy. New approaches
           to prevent relapse after AHCT and to treat relapse are needed.

        -  In murine models, we used ex vivo culture to generate rapamycin-resistant, Th1 (type 1 T
           helper cells)/Tc1 (T cytotoxic cells, type 1) polarized T cells (Th1/Tc1.Rapamycin
           (Rapa) cells) that were both rapamycin-resistant and apoptosis-resistant with an
           increased in vivo survival and in vivo function.

        -  Because Th1 /Tc1 polarized lymphocytes are pivotal in anti-tumor effects, we hypothesize
           that adoptive transfer of Th1/Tc1Rapa cells will be of benefit to MM patients.

      Objectives:

      Primary

      Dose escalation study

      Evaluate the feasibility and toxicity of an infusion of autologous, ex vivo
      rapamycin-generated, anti-cluster of differentiation 3 (CD3) and anti-cluster of
      differentiation 28 (CD28) co-stimulated, Th1/Tc1 lymphocytes (Th1/Tc1.Rapa cells) in subjects
      diagnosed with high-risk multiple myeloma following AHCT.

      MM Relapse Prevention and Treatment Cohorts

        -  For Cohort A, in newly diagnosed MM patients who have received AHCT, evaluate the safety
           of a defined regimen of Th1/Tc1.Rapa cell therapy and determine progression-free
           survival.

        -  For Cohort B, in relapsed MM, determine the partial response (PR)/complete response (CR)
           rate of Th1/Tc1.Rapa cell therapy.

      Eligibility:

        -  For Cohort A relapse prevention, patients with MM (normal- or high-risk) who are
           receiving induction therapy and subsequent AHCT.

        -  For Cohort B relapse therapy, patients with MM who have measurable disease after at
           least 2 prior treatment regimens.

      Design:

        -  For Cohort A, patients will receive two infusions of autologous Th1/Tc1.Rapa cells (at
           one and two months post-AHCT; each infusion preceded by a 7-day course of immune
           modulating chemotherapy [pentostatin plus low-dose cyclophosphamide; PC regimen].

        -  For Cohort B relapse therapy, patients will up to four infusions of Th1/Tc1.Rapa cells,
           with each infusion preceded by either a 7-day or 14-day PC regimen.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to insufficient accrual.
  </why_stopped>
  <start_date type="Actual">November 10, 2010</start_date>
  <completion_date type="Actual">August 16, 2017</completion_date>
  <primary_completion_date type="Actual">August 16, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With an Adverse Event Attributable to the Investigational Therapy</measure>
    <time_frame>2 months</time_frame>
    <description>Participants were assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Progression Free Survival in Cohort A Th1 (Type 1 T Helper Cells)/Tc1 (T Cytotoxic Cells, Type 1) Rapa Prevention of Relapse</measure>
    <time_frame>Study completion at 22 months</time_frame>
    <description>Progressive disease is assessed by the Consensus of the International Myeloma Working Group criteria and is defined as one or more of the following: Increases of greater or equal to 25% in serum M-component (minimum absolute increase of 0.5 g/dl) or urine M-component (minimum absolute increase of 200mg/24h) or percentage of bone marrow plasma cells (minimum absolute percentage of 10%) or size of bone lesions or new plasmacytoma, or development of hypercalcemia solely attributable to the disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Who Developed a Partial Response (PR)+Complete Response (CR) in Cohort B at Any Time Point Post Therapy With PR/CR Being Maintained Until Study Completed</measure>
    <time_frame>Study completion at 22 months</time_frame>
    <description>Patients whose tumors shrunk and were disease free after therapy in cohort B. Partial response and complete response were assessed by the Consensus of the International Myeloma Working Group criteria. Partial response is defined as 50% or greater reduction in serum M-protein and 90% or greater reduction in 24-h urinary M-protein (or to less than 200 mg per 24h), 50% or greater reduction in the size of soft tissue plasmacytomas, if present at baseline, no evidence of progressive or new bone lesions if radiographic studies were performed (X-rays not required in absence of clinical indication). Complete response is defined as negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and 5% or less plasma cells in bone marrow and no evidence of progressive or new bone lesion if radiographic studies were performed. Progressive disease is increases of â‰¥25% in serum M-component/urine M-component, or size of bone lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune Reconstitution in Recipients of Th1.(T Helper Cell) Rapa Cells.</measure>
    <time_frame>Baseline, prior to chemotherapy, and 2 weeks, 1, 2, and 3 months after final T cell infusion</time_frame>
    <description>Immune reconstitution in recipients of Th1.rapa cells was determined by flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)</measure>
    <time_frame>Date treatment consent signed to last date off study, 81 months and 6 days</time_frame>
    <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Myeloma, Plasma-Cell</condition>
  <condition>Myeloma-Multiple</condition>
  <condition>Myelomatosis</condition>
  <arm_group>
    <arm_group_label>Cohort B - Relapsed Multiple Myeloma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Th1 (type 1 T helper cells)/Tc1 (T cytotoxic cells, type 1) .Rapamycin (Rapa) for Relapsed Multiple Myeloma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A - Prevention of Relapse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Th1/Tc1.Rapa Prevention of Relapse</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Adoptive Immunotherapy</intervention_name>
    <description>Th1 (type 1 T helper cells)/Tc1 (T cytotoxic cells, type 1) Rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).</description>
    <arm_group_label>Cohort A - Prevention of Relapse</arm_group_label>
    <arm_group_label>Cohort B - Relapsed Multiple Myeloma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rapamycin-Generated Autologous Th1/Tc1 Cells (modified primary human T cells)</intervention_name>
    <description>Six Th1/Tc1 Rapa cell doses will be tested in cohorts of 1-6 subjects each: ranging from 10e(5) to 15 x 10e(6) cells/kg of body weight.</description>
    <arm_group_label>Cohort A - Prevention of Relapse</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Th1/Tc1 Rapa Cell Therapy</intervention_name>
    <description>Th1/Tc1Rapa: 5 x 10e(6) cells/kg</description>
    <arm_group_label>Cohort A - Prevention of Relapse</arm_group_label>
    <arm_group_label>Cohort B - Relapsed Multiple Myeloma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        MULTIPLE MYELOMA CRITERIA:

        Criteria for Cohort A (recently diagnosed subjects; to receive autologous hematopoietic
        cell transplantation (AHCT)):

          -  Must have presence of clonal plasma cells in the bone marrow greater or equal to 10%
             or biopsy proven plasmacytoma

          -  Must have either:

               1. presence of an M-component (Immunoglobulin G (IgG) or Immunoglobulin G (IgA)) in
                  serum greater or equal to 1g/dl or in urine greater or equal to 200 mg/24 h; or

               2. presence of an abnormal serum free light chain (FLC) ratio on the serum FLC
                  assay.

        Criteria for Cohort B (multiply relapsed multiple myeloma):

          -  Must have measurable multiple myeloma (MM), as defined by: serum M-protein greater
             than or equal to 1 g/dL, urine M-protein greater than or equal to 200 mg/24 hours,
             involved serum free light chain (FLC) level greater than or equal to 10 mg/dL, biopsy
             proven plasmacytoma, or more than 30% bone marrow plasma cells.

          -  Must have received at least 2 different treatment regimens for MM.

        Other eligibility criteria (applies to both Cohort A and Cohort B, unless specified):

          -  Age greater than or equal to 18 years and less than or equal to 75 years. In subjects
             between 65 and 75 years of age, physiologic age and co-morbidity will be thoroughly
             evaluated before enrolling. Specifically, any history of cardio-vascular pathology or
             symptoms, not clearly fitting the exclusion criteria will prompt an evaluation by a
             Clinical Center Cardiologist and eligibility will be considered on a case-by-case
             basis.

          -  For Cohort A only, high-dose chemotherapy and AHCT must be planned; with amendment K,
             post-transplant maintenance therapy will not be permitted.

          -  Karnofsky performance status (KPS) of 70% or greater. Lower KPS down to 50% may be
             acceptable if the restriction of activity is solely due to intractable pain from
             myeloma lesions.

          -  Ejection fraction (EF) by multi-gated acquisition scan (MUGA) or two-dimensional (2-D)
             echocardiogram within institution normal limits. In case of low EF, the subject may
             remain eligible after a stress echocardiogram is performed if the EF is more than 35%
             and if the increase in EF with stress is estimated at 10% or more.

          -  Serum creatinine less than or equal to 2.5 mg/dl,

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal
             to 3 times the upper limit of normal.

          -  Bilirubin less than or equal to1.5 (except if due to Gilbert's disease).

          -  Corrected carbon monoxide diffusing capacity (DLCO) greater than or equal to 50% on
             Pulmonary Function Tests

          -  No history of abnormal bleeding tendency or predisposition to repeated infections.

          -  Patients must be able to give informed consent

        EXCLUSION CRITERIA:

          -  Prior allogeneic stem cell transplantation

          -  Hypertension not adequately controlled by 3 or less medications.

          -  History of cerebro-vascular accident within 6 months of enrollment.

          -  History of documented pulmonary embolus within 6 months of enrollment.

          -  Clinically significant cardiac pathology: myocardial infarction within 6 months prior
             to enrollment, Class III or IV heart failure according to New York Heart Association
             (NYHA), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or
             electrocardiographic evidence of acute ischemia or active conduction system
             abnormalities.

          -  Patients with a history of coronary artery bypass grafting or angioplasty will receive
             a cardiology evaluation and be considered on a case-by-case basis.

          -  Human immunodeficiency virus (HIV) seropositive

          -  Patients known or found to be pregnant or who is unwilling to stop breast-feeding.

          -  Patients of childbearing age who are unwilling to practice contraception or other
             means of avoiding pregnancy.

        Patients may be excluded at the discretion of the principal investigator (PI) if it is
        deemed that allowing participation would represent an unacceptable medical or psychiatric
        risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Z Pavletic, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health (NIH) Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2011-C-0016.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.</citation>
    <PMID>18287387</PMID>
  </reference>
  <reference>
    <citation>Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990 Feb;33(2):86-9.</citation>
    <PMID>2301376</PMID>
  </reference>
  <reference>
    <citation>Tosi P, Zamagni E, Cellini C, Plasmati R, Cangini D, Tacchetti P, Perrone G, Pastorelli F, Tura S, Baccarani M, Cavo M. Neurological toxicity of long-term (&gt;1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol. 2005 Mar;74(3):212-6.</citation>
    <PMID>15693790</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 10, 2010</study_first_submitted>
  <study_first_submitted_qc>November 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2010</study_first_posted>
  <results_first_submitted>July 26, 2018</results_first_submitted>
  <results_first_submitted_qc>September 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 16, 2018</results_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute (NCI)</investigator_affiliation>
    <investigator_full_name>Steven Pavletic, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>High Risk</keyword>
  <keyword>Newly Diagnosed</keyword>
  <keyword>Adoptive Immunotherapy</keyword>
  <keyword>Autologous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT01239368/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT01239368/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>For the planned protocol cohort 7, no patients were accrued due to lack of feasibility in terms of T cell manufacturing. That is, cohort 6 evaluated 15X10EE6 cells per kg, which was the max. number that could be manufactured due to limiting reagents for cell culture. 3/34 pts signed consent but did not receive therapy due to progressive malignancy.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1 - 1x10(5) T Cells/kg</title>
          <description>1x10(5) Th1/Tc1 Rapa cells/kg of body weight</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2 - 5x10(5) T Cells/kg</title>
          <description>5x10(5) Th1/Tc1 Rapa cells/kg of body weight</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3 - 1x10(6) T Cells/kg</title>
          <description>1x10(6) Th1/Tc1 Rapa cells/kg of body weight</description>
        </group>
        <group group_id="P4">
          <title>Cohort 4 - 3x10(6) T Cells/kg</title>
          <description>3x10(6) Th1/Tc1 Rapa cells/kg of body weight</description>
        </group>
        <group group_id="P5">
          <title>Cohort 5 - 5x10(6) T Cells/kg</title>
          <description>5x10(6) Th1/Tc1 Rapa cells/kg of body weight</description>
        </group>
        <group group_id="P6">
          <title>Cohort 5B - 5x10(6) T Rapa Cells/kg</title>
          <description>5x10(6) Th1/Tc1 Rapa cells/kg of body weight; Three sequential infusions with at least two months between infusions.</description>
        </group>
        <group group_id="P7">
          <title>Cohort 6 - 15x10(6) T Cells/kg</title>
          <description>15x10(6) Th1/Tc1 Rapa cells/kg of body weight</description>
        </group>
        <group group_id="P8">
          <title>Cohort 7 - 45x10(6) T Cells/kg of</title>
          <description>45x10(6) Th1/Tc1 Rapa cells/kg of body weight</description>
        </group>
        <group group_id="P9">
          <title>Cohort A - Th1/Tc1.Rapa Prevention of Relapse</title>
          <description>Th1/Tc1.Rapa Prevention of Relapse
Adoptive Immunotherapy: Th1/Tc1 Rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).
Rapamycin-Generated Autologous Th1/Tc1 Rapa Cells: Six Th1.rapa cell doses will be tested in cohorts of 1-6 subjects each: ranging from 10e(5) to 15 x 10e(6) cells/kg of body weight.
Th1/Tc1 Rapa Cell Therapy: Th1/Tc1Rapa: 5 x 10e(6) cells/kg</description>
        </group>
        <group group_id="P10">
          <title>Cohort B - Th1/Tc1.Rapa for Relapsed Multiple Myeloma</title>
          <description>Th1/Tc1.Rapa for Relapsed Multiple Myeloma
Adoptive Immunotherapy: Th1/Tc1 Rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).
Th1/Tc1 Rapa Cell Therapy: Th1/Tc1rapa: 5 x 10e(6) cells/kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Principal investigator discretion</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression on study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused further treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>For the planned protocol cohort 7, no patients were accrued due to lack of feasibility in terms of T cell manufacturing. That is, cohort 6 evaluated 15X10EE6 cells per kg, which was the maximum number that could be manufactured due to limiting reagents for cell culture.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1 - 1x10(5) T Cells/kg</title>
          <description>1x10(5) Th1/Tc1.Rapa cells/kg of body weight</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2 - 5x10(5) T Cells/kg</title>
          <description>5x10(5) Th1/Tc1.Rapa cells/kg of body weight</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3 - 1x10(6) T Cells/kg</title>
          <description>1x10(6) Th1/Tc1.Rapa cells/kg of body weight</description>
        </group>
        <group group_id="B4">
          <title>Cohort 4 - 3x10(6) T Cells/kg</title>
          <description>3x10(6) Th1/Tc1.Rapa cells/kg of body weight</description>
        </group>
        <group group_id="B5">
          <title>Cohort 5 - 5x10(6) T Cells/kg</title>
          <description>5x10(6) Th1/Tc1.Rapa cells/kg of body weight</description>
        </group>
        <group group_id="B6">
          <title>Cohort 5B - 5x10(6) T Rapa Cells/kg</title>
          <description>5x10(6) Th1/Tc1.Rapa cells/kg of body weight; Three sequential infusions with at least two months between infusions.</description>
        </group>
        <group group_id="B7">
          <title>Cohort 6 - 15x10(6) T Cells/kg</title>
          <description>15x10(6) Th1/Tc1.Rapa cells/kg of body weight</description>
        </group>
        <group group_id="B8">
          <title>Cohort 7 - 45x10(6) T Cells/kg</title>
          <description>45x10(6) Th1/Tc1.Rapa cells/kg of body weight</description>
        </group>
        <group group_id="B9">
          <title>Cohort A - Th1/Tc1.Rapa Prevention of Relapse</title>
          <description>Th1/Tc1.Rapa Prevention of Relapse
Adoptive Immunotherapy: Th1/Tc1.Rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).
Rapamycin-Generated Autologous Th1/Tc1 Cells: Six Th1/Tc1.Rapa cell doses will be tested in cohorts of 1-6 subjects each: ranging from 10e(5) to 15 x 10e(6) cells/kg of body weight.
Th1/TC1 Rapa Cell Therapy: Th1/TC1rapa: 5 x 10e(6) cells/kg</description>
        </group>
        <group group_id="B10">
          <title>Cohort B - Th1/Tc1.Rapa for Relapsed Multiple Myeloma</title>
          <description>Th1/Tc1.Rapa for Relapsed Multiple Myeloma
Adoptive Immunotherapy: Th1/Tc1.Rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).
Th1/TC1 Rapa Cell Therapy: Th1/Tc1.Rapa: 5 x 10e(6) cells/kg</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="7"/>
            <count group_id="B6" value="5"/>
            <count group_id="B7" value="7"/>
            <count group_id="B8" value="0"/>
            <count group_id="B9" value="1"/>
            <count group_id="B10" value="5"/>
            <count group_id="B11" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.4" spread="13.58"/>
                    <measurement group_id="B2" value="41.3" spread="0"/>
                    <measurement group_id="B3" value="65.8" spread="0"/>
                    <measurement group_id="B4" value="46.7" spread="15.56"/>
                    <measurement group_id="B5" value="58.19" spread="13.79"/>
                    <measurement group_id="B6" value="57.64" spread="6.18"/>
                    <measurement group_id="B7" value="59.29" spread="9.58"/>
                    <measurement group_id="B9" value="66.9" spread="0"/>
                    <measurement group_id="B10" value="63.6" spread="9.08"/>
                    <measurement group_id="B11" value="55.8" spread="11.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With an Adverse Event Attributable to the Investigational Therapy</title>
        <description>Participants were assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)</description>
        <time_frame>2 months</time_frame>
        <population>For the planned protocol cohort 7, no patients were accrued due to lack of feasibility in terms of T cell manufacturing. That is, cohort 6 evaluated 15X10EE6 cells per kg, which was the maximum number that could be manufactured due to limiting reagents for cell culture.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - 1x10(5) T Cells/kg</title>
            <description>1x10(5) Th1/Tc1.Rapa cells/kg of body weight</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 - 5x10(5) T Cells/kg</title>
            <description>5x10(5) Th1/Tc1.Rapa cells/kg of body weight</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 - 1x10(6) T Cells/kg</title>
            <description>1x10(6) Th1/Tc1.Rapa cells/kg of body weight</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 - 3x10(6) T Cells/kg</title>
            <description>3x10(6) Th1/Tc1.Rapa cells/kg of body weight</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5 - 5x10(6) T Cells/kg</title>
            <description>5x10(6) Th1/Tc1.Rapa cells/kg of body weight</description>
          </group>
          <group group_id="O6">
            <title>Cohort 5B - - 5x10(6) T Cells/kg</title>
            <description>5x10(6) Th1/Tc1.Rapa cells/kg of body weight; Three sequential infusions with at least two months between infusions.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 6 - 15x10(6) T Cells/kg</title>
            <description>15x10(6) Th1/Tc1.Rapac ells/kg of body weight</description>
          </group>
          <group group_id="O8">
            <title>Cohort 7- 45x10(6) T Cells/kg</title>
            <description>45x10(6) Th1/Tc1.Rapa cells/kg of body weight</description>
          </group>
          <group group_id="O9">
            <title>Cohort A - Th1/Tc1.Rapa Prevention of Relapse</title>
            <description>Th1/Tc1.Rapa Prevention of Relapse
Adoptive Immunotherapy: Th1/Tc1.Rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).
Rapamycin-Generated Autologous Th1/Tc1 Cells: Six Th1/Tc1.Rapa cell doses will be tested in cohorts of 1-6 subjects each: ranging from 10e(5) to 15 x 10e(6) cells/kg of body weight.
Th1/Tc1 Rapa Cell Therapy: Th1/Tc1.Rapa 5 x 10e(6) cells/kg</description>
          </group>
          <group group_id="O10">
            <title>Cohort B - Th1/Tc1.Rapa Prevention of Relapse</title>
            <description>Th1/Tc1.Rapa for Relapsed Multiple Myeloma
Adoptive Immunotherapy: Th1.rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).
Th1/Tc1 Rapa Cell Therapy: Th1/Tc1.Rapa: 5 x 10e(6) cells/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With an Adverse Event Attributable to the Investigational Therapy</title>
          <description>Participants were assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)</description>
          <population>For the planned protocol cohort 7, no patients were accrued due to lack of feasibility in terms of T cell manufacturing. That is, cohort 6 evaluated 15X10EE6 cells per kg, which was the maximum number that could be manufactured due to limiting reagents for cell culture.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="1"/>
                <count group_id="O10" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Progression Free Survival in Cohort A Th1 (Type 1 T Helper Cells)/Tc1 (T Cytotoxic Cells, Type 1) Rapa Prevention of Relapse</title>
        <description>Progressive disease is assessed by the Consensus of the International Myeloma Working Group criteria and is defined as one or more of the following: Increases of greater or equal to 25% in serum M-component (minimum absolute increase of 0.5 g/dl) or urine M-component (minimum absolute increase of 200mg/24h) or percentage of bone marrow plasma cells (minimum absolute percentage of 10%) or size of bone lesions or new plasmacytoma, or development of hypercalcemia solely attributable to the disease.</description>
        <time_frame>Study completion at 22 months</time_frame>
        <population>The PFS was only used in cohort A, which had just one patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A - Th1/Tc1.Rapa Prevention of Relapse</title>
            <description>Th1/Tc1.Rapa Prevention of Relapse
Adoptive Immunotherapy: Th1 (type 1 T helper cells)/Tc1 (T cytotoxic cells, type 1) Rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).
Rapamycin-Generated Autologous Th1/Tc1.Rapa Cells: Six Th1.rapa cell doses will be tested in cohorts of 1-6 subjects each: ranging from 10e(5) to 15 x 10e(6) cells/kg of body weight.
Th1/Tc1 Rapa Cell Therapy: Th1/Tc1.Rapa: 5 x 10e(6) cells/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Progression Free Survival in Cohort A Th1 (Type 1 T Helper Cells)/Tc1 (T Cytotoxic Cells, Type 1) Rapa Prevention of Relapse</title>
          <description>Progressive disease is assessed by the Consensus of the International Myeloma Working Group criteria and is defined as one or more of the following: Increases of greater or equal to 25% in serum M-component (minimum absolute increase of 0.5 g/dl) or urine M-component (minimum absolute increase of 200mg/24h) or percentage of bone marrow plasma cells (minimum absolute percentage of 10%) or size of bone lesions or new plasmacytoma, or development of hypercalcemia solely attributable to the disease.</description>
          <population>The PFS was only used in cohort A, which had just one patient.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Who Developed a Partial Response (PR)+Complete Response (CR) in Cohort B at Any Time Point Post Therapy With PR/CR Being Maintained Until Study Completed</title>
        <description>Patients whose tumors shrunk and were disease free after therapy in cohort B. Partial response and complete response were assessed by the Consensus of the International Myeloma Working Group criteria. Partial response is defined as 50% or greater reduction in serum M-protein and 90% or greater reduction in 24-h urinary M-protein (or to less than 200 mg per 24h), 50% or greater reduction in the size of soft tissue plasmacytomas, if present at baseline, no evidence of progressive or new bone lesions if radiographic studies were performed (X-rays not required in absence of clinical indication). Complete response is defined as negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and 5% or less plasma cells in bone marrow and no evidence of progressive or new bone lesion if radiographic studies were performed. Progressive disease is increases of â‰¥25% in serum M-component/urine M-component, or size of bone lesions.</description>
        <time_frame>Study completion at 22 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort B - Th1/Tc1.Rapa for Relapsed Multiple Myeloma</title>
            <description>Th1/Tc1.Rapa for Relapsed Multiple Myeloma
Adoptive Immunotherapy: Th1 (type 1 T helper cells)/Tc1 (T cytotoxic cells, type 1) Rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).
Th1/Tc1 Rapa Cell Therapy: Th1/Tc1.Rapa: 5 x 10e(6) cells/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Developed a Partial Response (PR)+Complete Response (CR) in Cohort B at Any Time Point Post Therapy With PR/CR Being Maintained Until Study Completed</title>
          <description>Patients whose tumors shrunk and were disease free after therapy in cohort B. Partial response and complete response were assessed by the Consensus of the International Myeloma Working Group criteria. Partial response is defined as 50% or greater reduction in serum M-protein and 90% or greater reduction in 24-h urinary M-protein (or to less than 200 mg per 24h), 50% or greater reduction in the size of soft tissue plasmacytomas, if present at baseline, no evidence of progressive or new bone lesions if radiographic studies were performed (X-rays not required in absence of clinical indication). Complete response is defined as negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and 5% or less plasma cells in bone marrow and no evidence of progressive or new bone lesion if radiographic studies were performed. Progressive disease is increases of â‰¥25% in serum M-component/urine M-component, or size of bone lesions.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Reconstitution in Recipients of Th1.(T Helper Cell) Rapa Cells.</title>
        <description>Immune reconstitution in recipients of Th1.rapa cells was determined by flow cytometry.</description>
        <time_frame>Baseline, prior to chemotherapy, and 2 weeks, 1, 2, and 3 months after final T cell infusion</time_frame>
        <population>For the planned protocol cohort 7, no pts were accrued due to lack of feasibility in terms of T cell manufacturing. That is, cohort 6 evaluated 15X10EE6 cells per kg, which was the max. # that could be manufactured due to limiting reagents for cell culture. Outcome measure not done; data not collected in real-time due to premature closure of study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - 1x10(5) T Cells/kg</title>
            <description>1x10(5) Th1/Tc1.Rapa cells/kg of body weight</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 - 5x10(5) T Cells/kg</title>
            <description>5x10(5) Th1/Tc1.Rapa cells/kg of body weight</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 - 1x10(6) T Cells/kg</title>
            <description>1x10(6) Th1/Tc1.Rapa cells/kg of body weight</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 - 3x10(6) T Cells/kg</title>
            <description>3x10(6) Th1/Tc1.Rapa cells/kg of body weight</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5 - 5x10(6) T Cells/kg</title>
            <description>5x10(6) Th1/Tc1.Rapa cells/kg of body weight</description>
          </group>
          <group group_id="O6">
            <title>Cohort 5B - 5x10(6) Th1 Rapa Cells/kg</title>
            <description>5x10(6) Th1 rapa cells/kg of body weight; Three sequential infusions with at least two months between infusions.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 6 - 15x10(6) T Cells/kg</title>
            <description>15x10(6) Th1/Tc1.Rapa cells/kg of body weight</description>
          </group>
          <group group_id="O8">
            <title>Cohort 7 - 45x10(6) T Cells/kg</title>
            <description>45x10(6) Th1/Tc1.Rapa cells/kg of body weight</description>
          </group>
          <group group_id="O9">
            <title>Cohort A - Th1/Tc1.Rapa Prevention of Relapse</title>
            <description>Th1/Tc1.Rapa Prevention of Relapse
Adoptive Immunotherapy: Th1/Tc1.Rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).
Rapamycin-Generated Autologous Th1/Tc1 Cells: Six Th1/Tc1.Rapa cell doses will be tested in cohorts of 1-6 subjects each: ranging from 10e(5) to 15 x 10e(6) cells/kg of body weight.
Th1/Tc1 Rapa Cell Therapy: Th1/Tc1.Rapa: 5 x 10e(6) cells/kg</description>
          </group>
          <group group_id="O10">
            <title>Cohort B - Th1/Tc1.Rapa for Relapsed Multiple Myeloma</title>
            <description>Th1/Tc1.Rapa for Relapsed Multiple Myeloma
Adoptive Immunotherapy: Th1/Tc1.Rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).
Th1/Tc1 Rapa Cell Therapy: Th1/Tc1.Rapa: 5 x 10e(6) cells/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Reconstitution in Recipients of Th1.(T Helper Cell) Rapa Cells.</title>
          <description>Immune reconstitution in recipients of Th1.rapa cells was determined by flow cytometry.</description>
          <population>For the planned protocol cohort 7, no pts were accrued due to lack of feasibility in terms of T cell manufacturing. That is, cohort 6 evaluated 15X10EE6 cells per kg, which was the max. # that could be manufactured due to limiting reagents for cell culture. Outcome measure not done; data not collected in real-time due to premature closure of study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
            </class>
            <class>
              <title>Prior to chemotherapy</title>
            </class>
            <class>
              <title>2 weeks after final T-cell infusion</title>
            </class>
            <class>
              <title>1 month after final T-cell infusion</title>
            </class>
            <class>
              <title>2 months after final T-cell infusion</title>
            </class>
            <class>
              <title>3 months after final T-cell infusion</title>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)</title>
        <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
        <time_frame>Date treatment consent signed to last date off study, 81 months and 6 days</time_frame>
        <population>For the planned protocol cohort 7, no patients were accrued due to lack of feasibility in terms of T cell manufacturing. That is, cohort 6 evaluated 15X10EE6 cells per kg, which was the maximum number that could be manufactured due to limiting reagents for cell culture.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - 1x10(5) T Cells/kg</title>
            <description>1x10(5) Th1/Tc1.Rapa cells/kg of body weight</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 - 5x10(5) T Cells/kg</title>
            <description>5x10(5) Th1/Tc1.Rapa cells/kg of body weight</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 - 1x10(6) T Cells/kg</title>
            <description>1x10(6) Th1/Tc1.Rapa cells/kg of body weight</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 - 3x10(6) T Cells/kg</title>
            <description>3x10(6) Th1/Tc1.Rapa cells/kg of body weight</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5 - 5x10(6) T Cells/kg</title>
            <description>5x10(6) Th1/Tc1.Rapa cells/kg of body weight</description>
          </group>
          <group group_id="O6">
            <title>Cohort 5B - 5x10(6) T Cells/kg</title>
            <description>5x10(6) Th1/Tc1.Rapa cells/kg of body weight; Three sequential infusions with at least two months between infusions.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 6 - 15x10(6) T Cells/kg</title>
            <description>15x10(6) Th1/Tc1.Rapa cells/kg of body weight</description>
          </group>
          <group group_id="O8">
            <title>Cohort 7 - 45x10(6) T Cells/kg</title>
            <description>45x10(6) th1 cells/kg of body weight</description>
          </group>
          <group group_id="O9">
            <title>Cohort A - Th1/Tc1.Rapa Prevention of Relapse</title>
            <description>Th1/Tc1.Rapa Prevention of Relapse
Adoptive Immunotherapy: Th1.rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).
Rapamycin-Generated Autologous Th1/Tc1 Cells: Six Th1.rapa cell doses will be tested in cohorts of 1-6 subjects each: ranging from 10e(5) to 15 x 10e(6) cells/kg of body weight.
Th1/TC1 Rapa Cell Therapy: Th1/TC1rapa: 5 x 10e(6) cells/kg</description>
          </group>
          <group group_id="O10">
            <title>Cohort B - Th1/Tc1.Rapa for Relapsed Multiple Myeloma</title>
            <description>Th1/Tc1.Rapa for Relapsed Multiple Myeloma
Adoptive Immunotherapy: Th1.rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).
Th1/TC1 Rapa Cell Therapy: Th1/TC1rapa: 5 x 10e(6) cells/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)</title>
          <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
          <population>For the planned protocol cohort 7, no patients were accrued due to lack of feasibility in terms of T cell manufacturing. That is, cohort 6 evaluated 15X10EE6 cells per kg, which was the maximum number that could be manufactured due to limiting reagents for cell culture.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="1"/>
                <count group_id="O10" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Date treatment consent signed to last date off study, 81 months and 6 days.</time_frame>
      <desc>For the planned protocol cohort 7, no patients were accrued due to lack of feasibility in terms of T cell manufacturing. That is, cohort 6 evaluated 15X10EE6 cells per kg, which was the maximum number that could be manufactured due to limiting reagents for cell culture.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1 - 1x10(5) T Cells/kg</title>
          <description>1x10(5) Th1/Tc1.Rapa cells/kg of body weight</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2 - 5x10(5) T Cells/kg</title>
          <description>5x10(5) Th1/Tc1.Rapa cells/kg of body weight</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3 - 1x10(6) T Cells/kg</title>
          <description>1x10(6) Th1/Tc1.Rapa cells/kg of body weight</description>
        </group>
        <group group_id="E4">
          <title>Cohort 4 - 3x10(6) T Cells/kg</title>
          <description>3x10(6) Th1/Tc1.Rapa cells/kg of body weight</description>
        </group>
        <group group_id="E5">
          <title>Cohort 5 - 5x10(6) T Cells/kg</title>
          <description>5x10(6) Th1/Tc1.Rapa cells/kg of body weight</description>
        </group>
        <group group_id="E6">
          <title>Cohort 5B - 5x10(6) T Rapa Cells/kg</title>
          <description>5x10(6) Th1/Tc1.Rapa cells/kg of body weight; Three sequential infusions with at least two months between infusions.</description>
        </group>
        <group group_id="E7">
          <title>Cohort 6 - 15x10(6) T Cells/kg</title>
          <description>15x10(6) Th1/Tc1.Rapa cells/kg of body weight</description>
        </group>
        <group group_id="E8">
          <title>Cohort 7 - 45x10(6) T Cells/kg</title>
          <description>45x10(6) Th1/Tc1.Rapa cells/kg of body weight</description>
        </group>
        <group group_id="E9">
          <title>Cohort A - Th1/Tc1.Rapa Prevention of Relapse</title>
          <description>Th1/Tc1.Rapa Prevention of Relapse
Adoptive Immunotherapy: Th1/Tc1.Rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).
Rapamycin-Generated Autologous Th1/Tc1 Cells: Six Th1.rapa cell doses will be tested in cohorts of 1-6 subjects each: ranging from 10e(5) to 15 x 10e(6) cells/kg of body weight.
Th1/TC1 Rapa Cell Therapy: Th1/TC1rapa: 5 x 10e(6) cells/kg</description>
        </group>
        <group group_id="E10">
          <title>Cohort B - Th1/Tc1.Rapa for Relapsed Multiple Myeloma</title>
          <description>Th1/Tc1.Rapa for Relapsed Multiple Myeloma
Adoptive Immunotherapy: Th1/Tc1.Rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).
Th1/TC1 Rapa Cell Therapy: Th1/TC1rapa: 5 x 10e(6) cells/kg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Progressive disease</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="7" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" events="10" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="6" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="7" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E6" events="5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>CPK increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Papulopustular rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>3/34 pts signed consent but never received therapy due to progressive malignancy that precluded their ability to receive the experimental therapy. These participants were not assigned to a cohort.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Steven Pavletic</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>301-402-4899</phone>
      <email>steven_pavletic@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

